A recent analysis of 1,220 patients suggests testosterone improved some menopause symptoms, but experts caution the strongest evidence remains limited to HSDD.
On October 2, 2026, a new report shared findings about testosterone use among perimenopausal and menopausal women. The story was distributed by Stacker and produced by Hone Health. It detailed a comprehensive analysis of data from 1,220 female patients. This release arrives at a time when testosterone prescriptions for women have reportedly grown at a rapid pace.
The same report noted that prescriptions to women nearly tripled from 2016 to 2025. Understanding what this data actually means requires a careful look at how it was collected. It also requires contrasting these company findings with established medical guidelines.
To fully grasp the landscape, it helps to understand why these reports matter to the public right now. The intersection of midlife hormonal changes and sexual wellness often produces complex questions for women. When new data emerges regarding off-label treatments, it can easily create confusion about what the evidence actually proves. This recent analysis attempts to quantify how certain patients felt while undergoing therapy.
However, reading beyond the headline is necessary to separate observational trends from rigorously tested clinical outcomes. Menopause and perimenopause bring a variety of physical shifts that can affect daily comfort and intimate relationships. Because of this, any report highlighting potential relief quickly gains attention from adults seeking practical answers. We must look closely at the methodology to see if the optimism is truly warranted by the science.
The analysis focused specifically on a group of 1,220 women in perimenopause or menopause. These patients all held an active testosterone prescription through Hone Health. Importantly, they did not have any recorded estrogen, estradiol, or progesterone prescriptions in the company records. By isolating this specific group, the reviewers aimed to track the solitary impact of testosterone therapy.
Researchers utilized the Menopause Quality of Life Questionnaire to evaluate the patients during their treatment. This assessment tool is commonly known as MENQOL. It scores various physical and emotional symptoms on a scale from 0 to 6. Lower scores on this scale indicate that a patient is experiencing fewer bothersome issues in their daily life.
To measure progress, the reviewers compared each patient's first symptom assessment against their most recent one. Any women with fewer than two assessments were entirely excluded from the final data set. This methodology allowed the company to observe symptom changes over a period of time. It provides a descriptive snapshot of how this specific group of patients felt during their treatment.
Tracking these specific patients allowed the company to isolate individuals who were not taking supplementary estrogen. This distinction is vital when attempting to evaluate a single hormone's impact on complex midlife symptoms. However, the report explicitly notes a major gap in this tracking approach. The records reflect only what was prescribed directly through the company's own pharmacy network.
While the sample size is large, the design of the data collection is straightforward and entirely observational. The company relied strictly on self-reported survey scores rather than clinical lab verifications of physical changes. This reliance on symptom questionnaires is standard for tracking personal comfort but has inherent analytical limits. Evaluating subjective scores requires careful interpretation when discussing broader medical efficacy.
According to the report, participants saw broad improvements across 18 different menopause symptoms. The largest reported gains appeared in areas relating to sexual desire, energy, strength, and stamina. For many individuals dealing with midlife transitions, these specific areas represent significant quality of life concerns. Hearing that a large group of patients felt better can certainly sound encouraging on the surface.
Hone-affiliated physician Dr. Natalie Kunsman reviewed the findings and offered her perspective. She stated that the reported symptom pattern aligned with her personal understanding of how testosterone affects the body. However, Dr. Kunsman also argued that standard symptom scores might only capture a small portion of the actual effects. Her commentary reflects a clinical viewpoint rather than a rigidly proven outcome of the analysis itself.
It is also important to note what the available report did not include. The text did not provide specific numerical sizes for the claimed symptom improvements. It simply outlined a general trend of positive change in categories like desire, libido, and arousal.
Without exact numbers, readers are left with a qualitative summary rather than a precise clinical measurement. The phrase "largest gains" indicates a relative improvement compared to other symptoms on the survey list. It does not guarantee that the improvement was large enough to completely resolve the underlying issue. This lack of numerical detail makes it difficult to compare these findings against established scientific trials.
Furthermore, Dr. Kunsman's commentary highlights the inherent difficulty of measuring human sexual experience through a simple questionnaire. Emotional well-being and physical vitality are heavily influenced by a wide variety of lifestyle factors. While the survey captures a positive trend, it cannot definitively explain why the patients felt better. The reported gains remain an interesting observation rather than a confirmed biological breakthrough.
It is critical to recognize that these findings are entirely observational in nature. The analysis completely lacked a randomized control group, which remains the gold standard for proving medical outcomes. Because of this design, the data can only show a simple association between the prescription and the survey scores. The results absolutely do not establish that testosterone directly caused the reported symptom improvements.
Furthermore, the data relies exclusively on internal prescription records held by Hone Health. The report explicitly noted that hormone treatments obtained through other medical providers might not be captured in their system. This missing information creates a potential gap in understanding the full picture of patient care. Some women might have been using additional hormones simultaneously without the company knowing.
Another crucial limitation involves the source of the report itself. The analysis was produced directly by a company, rather than being conducted by an independent research team. It was also not structured as a rigorous clinical trial designed to eliminate bias and confounding factors. Observational data from a commercial provider often lacks the strict oversight found in academic medical research.
Because there is no control group, placebo effects cannot be ruled out as a contributing factor. Patients who expect to feel better after starting a new treatment often report subjective improvements on questionnaires. While their positive feelings are genuine, they do not automatically prove the biological efficacy of the medication.
The absence of a control group also means that natural symptom fluctuations were not accounted for in the data. Menopause symptoms frequently shift, peak, and resolve on their own over time. Without a group of untreated women for comparison, it is impossible to know how many symptoms would have improved naturally. This inherent uncertainty is exactly why observational data is treated with caution by the medical community.
The release of this company data coincided with a major regulatory meeting focused on the same topic. In September 2026, the FDA held a public workshop regarding testosterone use in menopausal women. During this gathering, experts carefully discussed the current evidence and highlighted significant knowledge gaps. Currently, testosterone is not FDA-approved for women in the United States and is exclusively prescribed off-label.
Expert accounts of the FDA workshop presented a much narrower view of testosterone therapy than the company report. According to Medscape, the international panel found evidence sufficient only for hypoactive sexual desire disorder. This clinical condition is commonly referred to as HSDD. The panel noted this evidence applies primarily to appropriately selected postmenopausal women.
Even within this specific diagnosis, the experts characterized the demonstrated benefit for sexual desire as modest. This conservative assessment stands in contrast to broad claims about transforming midlife vitality. The workshop experts also specifically addressed wider claims regarding understanding hormonal changes and physical energy. They firmly stated that potential benefits for energy, mood, memory, and muscle need much more study.
The current clinical consensus simply does not support prescribing testosterone for general well-being or routine fatigue. Medical leaders are waiting for rigorous, long-term studies to verify these broader lifestyle claims. Until that rigorous evidence exists, established guidance will remain focused on safely treating specific, diagnosed sexual desire disorders.
The contrast between the company report and the FDA workshop highlights a common tension in sexual wellness education. On one side, observational data suggests broad improvements across numerous physical and emotional symptoms. On the other side, regulatory panels demand highly controlled proof before validating any specific medical claim. The September 2026 workshop served as an important reminder of these strict evidence standards.
Observational data can offer interesting clues about how some patients feel during their treatment journeys. However, a positive association in a company report is not the same as a proven medical outcome. You should not view a general symptom list as definitive proof that testosterone is the right choice for you. If you are experiencing distressing changes in your sexual wellbeing, specific and clear communication is vital.
The best approach is to describe the exact physical or emotional shift that is troubling you. If persistently low desire causes you distress, discuss that specific symptom with a qualified clinician. A medical professional can help you separate temporary biological shifts from persistent health changes. They can also ensure that any potential treatments align with established, evidence-based guidelines.
It is also important to remember that hormone therapy involves ongoing evaluation and careful monitoring. The available sources in this report do not establish the long-term safety of the treatment. Regulatory reviews frequently point to a lack of long-term safety data regarding cardiovascular and other health concerns. Taking a cautious, informed approach protects your overall wellbeing while addressing specific intimacy concerns.
It is entirely normal to seek solutions when your body goes through significant hormonal transitions. However, reacting to observational headlines without consulting a professional can lead to mismatched expectations. The current evidence supports a very specific application of testosterone therapy for a very specific diagnosis. Broadening that application to treat general fatigue or mood changes is simply not supported by the medical consensus.
Your sexual wellbeing deserves personalized attention from a professional who understands your complete medical history. They can help you discuss intimacy, relationships, and connection alongside any physical health evaluations. By communicating your specific symptoms clearly, you build a foundation for effective and safe care. Let the established clinical evidence guide your choices, rather than relying solely on company-reported survey trends.
Maintaining a fulfilling intimate life during midlife transitions requires a calm review of the facts. While new patient data can highlight interesting trends, objective evidence remains your best tool for making informed choices.
Evaluating observational symptom reports against proven clinical evidence requires clear and objective context. Sexential addresses the difficulty of separating hormonal, physical, psychological and relationship factors, helping adults safely interpret new health data. We explain sexual function, desire, confidence and aging without sensationalism, providing the mature information you need to make informed choices.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
Prostate Cancer UK's October 2026 guidance explains how medical treatments affect physical desire and offers practical ways for couples to adapt intimacy.
A single lab result or physical symptom cannot diagnose a testosterone deficiency. Learn why clinical guidelines require repeated testing and broader context.
Learn how responsive desire offers an alternative to spontaneous arousal. Understand how hormones, relationships, and physical comfort shape midlife intimacy.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
